Evaluation of the efficacy of topical Gabapentin for the treatment of pruritus in patients with Epidermolysis bullosa

Evaluation of the efficacy of topical Gabapentin for the treatment of pruritus in patients with Epidermolysis bullosa, Faghihi hospital, 2021

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210822052258N1

Enrollment

Registered

2021-09-15

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis bullosa. Epidermolysis bullosa

Interventions

Intervention 1: Intervention group: Intervention group receives topical Gabapentine 10%(plus 10%Glycerine in base of cold cream)formulized and prepared in Dr.Rastegar pharmacy on the assigned side 3 t

Eligibility

Sex/Gender

All

Age

6 Years to No maximum

Inclusion criteria

Inclusion criteria: Age equal or more than 6 years; Histologically confirmed any three major forms of epidermolysis bullosa (EB simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB)) complain of persistent pruritic lesions unresponsive to the standard treatment

Exclusion criteria

Exclusion criteria: Use of oral gabapentin Pregnancy or lactation Concomitant kidney, liver, blood, thyroid, and psychiatric diseases or any other systemic disease that may cause pruritus

Design outcomes

Primary

Measure	Time frame
Itching. Timepoint: Baseline and at the end of treatment (end of 6th week). Method of measurement: Leuven_itch_scale.;Pruritic area size. Timepoint: Baseline and at the end of treatment (end of 6th week). Method of measurement: (Length × width) ÷ 2.;Erythema. Timepoint: Baseline and at the end of treatment (end of 6th week). Method of measurement: Examination: absent (0), mild (pink-1), moderate (pink to red-2), severe (red-3).	—

Measure

Time frame

Itching. Timepoint: Baseline and at the end of treatment (end of 6th week). Method of measurement: Leuven_itch_scale.;Pruritic area size. Timepoint: Baseline and at the end of treatment (end of 6th week). Method of measurement: (Length × width) ÷ 2.;Erythema. Timepoint: Baseline and at the end of treatment (end of 6th week). Method of measurement: Examination: absent (0), mild (pink-1), moderate (pink to red-2), severe (red-3).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Vahedi

Shiraz University of Medical Sciences

svhd7988@gmail.com+98 71 3235 1087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026